| NCT02360397 | Ventricular Premature Complexes|Myocardial Ischemia | Drug: ranolazine | Kent Hospital, Rhode Island|Gilead Sciences | Phase 2 | 2014-12-01 | 2016-09-01 |
| NCT02239926 | Diarrhea Predominant Irritable Bowel Syndrome | Drug: Ranolazine|Drug: Placebo | Mayo Clinic | Phase 2|Phase 3 | 2014-09-01 | 2016-02-16 |
| NCT01705509 | Cardiomyopathy | Drug: Ranolazine | Cardiovascular Institute of the South Clinical Research Corporation|Gilead Sciences | | 2012-09-01 | 2016-01-26 |
| NCT01996618 | Premature Ventricular Beats | Drug: Ranolazine | Walter Reed National Military Medical Center | Phase 4 | 2014-01-01 | 2015-04-30 |
| NCT01435174 | End-stage Renal Disease|Cardiovascular Disease | Drug: Ranolazine|Procedure: Pharmacokinetic Blood and Dialysate Sampling|Procedure: QT Interval | University of Michigan|Gilead Sciences | Phase 4 | 2011-10-01 | 2014-06-24 |
| NCT02251457 | Myotonia Congenita (Enrollment Complete)|Paramyotonia Congenita|Myotonic Dystrophy 1 | Drug: Ranolazine | Ohio State University|Gilead Sciences | Phase 2 | 2014-08-01 | 2017-03-18 |
| NCT02133352 | Pulmonary Hypertension|Diastolic Left Ventricular Dysfunction | Drug: Ranolazine | Harrison Farber|Gilead Sciences|Boston University | Phase 4 | 2011-07-01 | 2014-05-06 |
| NCT01304095 | Coronary Artery Disease|Angina|Metabolic Syndrome | Drug: Ranolazine | Atlanta Heart Specialists, LLC|Gilead Sciences | Phase 4 | 2011-01-01 | 2013-07-09 |
| NCT01546597 | Type 2 Diabetes Mellitus | Drug: Metformin|Drug: Ranolazine | Gilead Sciences | Phase 1 | 2012-02-01 | 2012-07-09 |
| NCT02252406 | Stable Angina|Metabolic Syndrome | Drug: Ranolazine|Drug: Placebo | University of Florida | Phase 4 | 2015-09-01 | 2017-02-02 |
| NCT01546558 | Type 2 Diabetes Mellitus | Drug: Metformin|Drug: Ranolazine | Gilead Sciences | Phase 1 | 2012-02-01 | 2012-07-09 |
| NCT02156336 | Diabetic Peripheral Neuropathic Pain | Drug: Ranolazine|Drug: Placebo | Horizons International Peripheral Group|Gilead Sciences | Phase 4 | 2014-05-01 | 2017-02-09 |
| NCT01174173 | Angina|Pulmonary Arterial Hypertension | Drug: Ranolazine | Northwestern University|Gilead Sciences | Phase 3 | 2010-06-01 | 2015-04-22 |
| NCT01767987 | Acute Coronary Syndrome | Drug: Ranolazine|Drug: Placebo | Harvey Hahn|Gilead Sciences|Kettering Health Network | Phase 2 | 2012-11-01 | 2015-10-20 |
| NCT02147067 | Microvascular Angina | Drug: Ranolazine|Drug: Placebo | Emory University|Gilead Sciences | Phase 4 | 2014-09-01 | 2016-07-27 |
| NCT01558830 | Chronic Stable Angina|Coronary Artery Disease|Atrial Fibrillation|Ventricular Tachycardia | Drug: ranolazine|Drug: placebo | Cardiovascular Consultants of Nevada|Gilead Sciences | Phase 4 | 2012-01-01 | 2012-03-20 |
| NCT01721967 | Hypertrophic Cardiomyopathy | Drug: Ranolazine | Duke University|Gilead Sciences | Phase 4 | 2012-11-01 | 2017-01-19 |
| NCT03044964 | Angina | Drug: Ranolazine|Drug: Placebo | Amit Malhotra, MD|Gilead Sciences|Stern Cardiovascular Foundation, Inc. | Phase 4 | 2017-01-10 | 2017-02-03 |
| NCT01345188 | Cardiomyopathy|Chest Pain|Dyspnea | Drug: Ranexa|Drug: Placebo | Midwest Cardiovascular Research Foundation|Gilead Sciences | Phase 4 | 2011-04-01 | 2014-09-24 |
| NCT01163721 | Diabetes Mellitus, Type 2 | Drug: Ranolazine|Drug: Placebo | Gilead Sciences | Phase 2 | 2010-06-01 | 2013-07-19 |
